-
cover and contents
Abstract
(
112)
PDF (9531 KB) (
325
)
2022, Vol.55(4): 0–0
-
Expert consensus on rational application of topical agents and patient education for atopic dermatitis
Abstract
(
1195)
PDF (24310 KB) (
196
)
2022, Vol.55(4): 281–288 doi: https://doi.org/10.35541/cjd.20210833
-
Expert consensus on clinical application of wet-wrap therapy for atopic dermatitis
Abstract
(
913)
PDF (9134 KB) (
1575
)
2022, Vol.55(4): 289–294 doi: https://doi.org/10.35541/cjd.20210823
-
Clinical efficacy and safety of dupilumab in the treatment of atopic dermatitis
Abstract
(
800)
PDF (6048 KB) (
719
)
2022, Vol.55(4): 295–298 doi: https://doi.org/10.35541/cjd.20210736
-
Analysis of short-term efficacy and safety of the first subcutaneous injection of dupilumab in the treatment of moderate-to-severe childhood atopic dermatitis
Abstract
(
891)
PDF (7547 KB) (
35
)
2022, Vol.55(4): 299–303 doi: https://doi.org/10.35541/cjd.20210734
-
Efficacy and safety of baricitinib in the treatment of moderate-to-severe atopic dermatitis: a clinical observation
Abstract
(
1322)
PDF (6105 KB) (
547
)
2022, Vol.55(4): 304–307 doi: https://doi.org/10.35541/cjd.20210474
-
Clinical features and classification of 180 patients with morphea
Abstract
(
407)
PDF (16449 KB) (
34
)
2022, Vol.55(4): 308–315 doi: https://doi.org/10.35541/cjd.20210724
-
Retrospective analysis of 201 clinical isolates of Aspergillus fumigatus from a hospital in Nanjing: clinical characteristics of infected patients and azole resistance
Abstract
(
376)
PDF (7512 KB) (
2
)
2022, Vol.55(4): 316–320 doi: https://doi.org/10.35541/cjd.20210646
-
Exploration of the effect of EphB2 inhibitors on cutaneous squamous cell carcinoma and their mechanisms of action based on Wnt/β-catenin signaling pathway
Abstract
(
277)
PDF (15252 KB) (
4
)
2022, Vol.55(4): 321–328 doi: https://doi.org/10.35541/cjd.20210526
-
Skin microecology in patients with severe atopic dermatitis at acute and remission phases
Abstract
(
411)
PDF (17639 KB) (
10
)
2022, Vol.55(4): 329–336 doi: https://doi.org/10.35541/cjd.20210824
-
Dupilumab facial redness caused by the treatment with dupilumab in a case of atopic dermatitis
Abstract
(
610)
PDF (6796 KB) (
39
)
2022, Vol.55(4): 337–338 doi: https://doi.org/10.35541/cjd.20210453
-
Two cases of severe prurigo phenotype of atopic dermatitis treated with dupilumab
Abstract
(
782)
PDF (10601 KB) (
31
)
2022, Vol.55(4): 339–341 doi: https://doi.org/10.35541/cjd.20210027
-
A case of livedoid vasculopathy complicated by hyperhomocysteinemia
Abstract
(
350)
PDF (8831 KB) (
5
)
2022, Vol.55(4): 341–342 doi: https://doi.org/10.35541/cjd.20200699
-
A case of superficial CD34-positive fibroblastic tumor
Abstract
(
651)
PDF (8340 KB) (
29
)
2022, Vol.55(4): 343–344 doi: https://doi.org/10.35541/cjd.20200326
-
Calcium-based antimicrobial peptide compounds cooling gel for the treatment of atopic dermatitis: a randomized, double-blind controlled clinical study
Abstract
(
666)
PDF (5961 KB) (
468
)
2022, Vol.55(4): 345–348 doi: https://doi.org/10.35541/cjd.20210342
-
Heterogeneity across skin sites in atopic dermatitis
Abstract
(
770)
PDF (6315 KB) (
15
)
2022, Vol.55(4): 349–352 doi: https://doi.org/10.35541/cjd.20210865
-
Chinese Medical Association-L′Oréal China Skin & Hair Grant result summary--scalp and hair
Abstract
(
743)
PDF (5958 KB) (
610
)
2022, Vol.55(4): 353–356 doi: https://doi.org/10.35541/cjd.20210750
-
Mechanisms of pruritus in atopic dermatitis
Abstract
(
594)
PDF (7314 KB) (
61
)
2022, Vol.55(4): 357–361 doi: https://doi.org/10.35541/cjd.20201117
-
Role of the autonomic nervous system in immune imbalance in atopic dermatitis
Abstract
(
342)
PDF (5922 KB) (
3
)
2022, Vol.55(4): 362–365 doi: https://doi.org/10.35541/cjd.20210298
-
Transcriptomics in atopic dermatitis
Abstract
(
325)
PDF (15736 KB) (
12
)
2022, Vol.55(4): 365–369 doi: https://doi.org/10.35541/cjd.20210333
-
Research advances in systemic lupus erythematosus in 2021
Abstract
(
1329)
PDF (5927 KB) (
76
)
2022, Vol.55(4): 369–372 doi: https://doi.org/10.35541/cjd.20210898